Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia

Schizophrenia Research

Volumn 98, Issue 1-3, 2008, Pages 8-15

  Mullins, C Daniel ^a   Obeidat, Nour A ^a   Cuffel, Brian J ^b   Naradzay, John ^a   Loebel, Antony D ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b PFIZER INC   (United States)

Author keywords

Adherence; Atypical antipsychotics; Discontinuation; Medicaid; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCHIZOPHRENIA; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL RATE; THIAZOLES;

EID: 37049011433     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.04.035     Document Type: Article

References (26)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 2 (2004) 596-601
2. Eaddy M., Grogg A., and Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin. Ther. 27 2 (2005) 263-272
3. Gilbody S.M., Bagnall A.M., Duggan L., et al. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. 3 (2000) (CD002306)
4. Jaffe A.B., and Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J. Clin. Psychiatry 64 Suppl 17 (2003) 3-6
5. Keith S.J., and Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. J. Clin. Psychiatry 64 11 (2003) 1308-1315
6. Kemmler G., Hummer M., Widschwendter C., et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch. Gen. Psychiatry 62 12 (2005) 1305-1312
7. Knapp M., King D., Pugner K., et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br. J. Psychiatry 184 (2004) 509-516
8. Kuno E., and Rothbard A.B. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am. J. Psychiatry 159 4 (2002) 567-572
9. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63 10 (2002) 892-909
10. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
11. Lung C., Loebel A.D., Lombardo I.D., et al. Treatment Persistence and Antipsychotic Therapy: Results of a Longitudinal Pharmacy Claims Database Analysis. Poster presented at the annual meeting of the American Psychiatric Association, Toronto, Canada (2006) May
12. Mallinger J.B., Fisher S.G., Brown T., et al. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr. Serv. 57 1 (2006) 133-136
13. Naber D., and Vita A. Tools for measuring clinical effectiveness. Eur. Neuropsychopharmacol. 14 Suppl 4 (2004) S435-S444
14. Nieto F.J., and Coresh J. Adjusting survival curves for confounders: a review and a new method. Am. J. Epidemiol. 143 10 (1996) 1059-1068
15. Opolka J.L., Rascati K.L., Brown C.M., et al. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr. Serv. 55 2 (2004) 151-156
16. Pelagotti F., Santarlasci B., Vacca F., et al. Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur. J. Clin. Pharmacol. 59 12 (2004) 905-909
17. Santarlasci B., and Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann. Pharmacother. 37 4 (2003) 556-563
18. Sikka R., Xia F., and Aubert R.E. Estimating medication persistency using administrative claims data. Am. J. Manag. Care 11 7 (2005) 449-457
19. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. 50 1 (1997) 105-116
20. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163 4 (2006) 611-622
21. Sullivan G., Wells K.B., Morgenstern H., et al. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am. J. Psychiatry 152 12 (1995) 1749-1756
22. Svarstad B.L., Shireman T.I., and Sweeney J.K. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr. Serv. 52 6 (2001) 805-811
23. Tamminga C.A. Practical treatment information for schizophrenia. Am. J. Psychiatry 163 4 (2006) 563-565
24. Thieda P., Beard S., Richter A., et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv. 54 4 (2003) 508-516
25. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 21 3 (1995) 419-429
26. Weiden P.J., Kozma C., Grogg A., et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv. 55 8 (2004) 886-891